Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04129931 · ClinicalTrials.gov registry record · Phase 2
PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study
A Phase 2 study of Asthma, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 395
- Enrollment target
- 20
- Study locations
NCT04129931: Completed Phase 2 study of Asthma, sponsored by University of North Carolina, Chapel Hill.
NCT04129931 is a Phase 2 study of Asthma that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 395 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04129931, a Phase 2 study of Asthma, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 395 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate several interventions given to participants with severe asthma. Interventions are administered in a crossover manner with 16-week treatment periods followed by 8 to 16 week washout.
Primary Outcome
Assessed prior to bronchodilator administration. Efficacy analyses will compare the end-of-period outcome values between test treatment and placebo.
Conditions Studied
Interventions
- DRUG Imatinib Mesylate
- DRUG Clazakizumab
- DRUG MCT
- DRUG Broncho-Vaxom
- DRUG Cavosonstat
Study Locations (20)
Illinois
- University of Illinois at Chicago - Chicago
- Ann & Robert H. Lurie Children's Hospital - Chicago
- Northwestern Universtiy - Chicago
- Rush University - Chicago
- University of Chicago - Chicago
California
- University of California Davis - Sacramento
- University of California San Diego: Airway Research & Clinical Trials Center - San Diego
- University of California San Diego: La Jolla Altman Clinical Translation Research Institute - San Diego
- University of California San Francisco - San Francisco
Colorado
- Children's Hospital Colorado - Aurora
- University of Colorado Denver - Aurora
- National Jewish Health - Denver
Arizona
- Mayo Clinic Scottsdale - Scottsdale
- University of Arizona Tucson - Tucson
Massachusetts
- Boston Children's Hospital - Boston
- Brigham and Women's Hospital - Boston
Connecticut
- Yale University - New Haven
Florida
- University of South Florida - Tampa
Indiana
- Riley Hospital for Children - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 395 participants |
| Start Date | 2019-12-19 |
| Est. Completion | 2025-03-19 |
| Phase | Phase 2 |
What the finished NCT04129931 record still lists
NCT04129931 is an interventional study that assigns participants to a tested intervention. The registered 395 participants enrollment target is mid-sized for trials with a published cap, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 5 interventions - of which Imatinib Mesylate is the first listed.
NCT04129931 names 20 study sites across 9 states, led by Illinois, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT04129931 about?
NCT04129931 is a clinical study titled "PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study". The primary objective of this study is to evaluate several interventions given to participants with severe asthma. Interventions are administered in a crossover manner with 16-week treatment periods followed by 8 to 16 week washout.
What is the current status of trial NCT04129931?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 395 participants. The study started on 2019-12-19. Estimated completion is 2025-03-19.
What conditions does trial NCT04129931 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT04129931?
The interventions under investigation include: Imatinib Mesylate (DRUG), Clazakizumab (DRUG), MCT (DRUG), Broncho-Vaxom (DRUG), Cavosonstat (DRUG).
Who is sponsoring clinical trial NCT04129931?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04129931 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04129931's enrollment target sits among peer trials
395 96th of 374 higher than 278 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07207369 · 395 participants · Phase 3
A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
- NCT05633615 · 396 participants · Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06227910 · 396 participants · Phase 3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- NCT06545331 · 396 participants · Phase 1
Study of XB010 in Subjects With Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI